Ginkgo Bioworks Holdings, Inc. (DNA, Financial) saw its stock price fall by 5.03%, currently trading at $10.16 per share with a trading volume of 485,937 shares and a turnover rate of 0.85%. Recent financial reports indicate revenue of $89.05 million, a net loss of $56.40 million, and earnings per share of -$1.08. The gross profit stands at $59.87 million with a P/E ratio of -0.79. Among the six rating agencies, 17% recommend buying, 17% suggest holding, and 66% advise selling.
Within the biotechnology sector, which fell by 1.12%, Trevi Therapeutics, Inc. and Palisade Bio, Inc. showed significant gains. Palisade Bio, Inc. also had a high turnover rate of 3892.10% and a notable amplitude of 99.29%.
Ginkgo Bioworks specializes in cell programming, offering services across various markets, including food, agriculture, pharmaceuticals, and chemicals, with two main segments: Foundry and Biosecurity.
